Your browser doesn't support javascript.
loading
Endoscopic ultrasound-guided radiofrequency ablation of premalignant pancreatic-cystic neoplasms and neuroendocrine tumors: prospective study.
Younis, Fadi; Ben-Ami Shor, Dana; Lubezky, Nir; Geva, Ravit; Osher, Esther; Shibolet, Oren; Phillips, Adam; Scapa, Erez.
Afiliación
  • Younis F; Departments of Gastroenterology and Liver Disease.
  • Ben-Ami Shor D; Departments of Gastroenterology and Liver Disease.
  • Lubezky N; Surgery.
  • Geva R; Oncology.
  • Osher E; Endocrinology, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Israel.
  • Shibolet O; Departments of Gastroenterology and Liver Disease.
  • Phillips A; Departments of Gastroenterology and Liver Disease.
  • Scapa E; Departments of Gastroenterology and Liver Disease.
Eur J Gastroenterol Hepatol ; 34(11): 1111-1115, 2022 11 01.
Article en En | MEDLINE | ID: mdl-36170679
BACKGROUND: Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is a developing therapeutic approach for premalignant pancreatic-cystic neoplasms (PCNs) and small pancreatic neuroendocrine tumors (PNETs). The safety and efficacy of pancreatic EUS-RFA were previously reported in small series. Herein we report our initial experience with RFA of PCNs and small PNETs. METHODS: This is a prospective single-center study including 12 patients with a median follow-up of 7 months, with either PCN or PNET <2 cm. Eligible PCNs were either intraductal papillary mucinous neoplasms (IPMN) with worrisome features or mucinous cystic neoplasms (MCN) that were not eligible or refused surgery. Ablation was performed using a 19-gauge dedicated needle. RESULTS: Twelve patients were treated, five had PCNs (four IPMNs, one MCN; median size of 36 mm, range 12-60) and seven had PNETs (median size 8.9 mm, range 6-18). Among patients with PCNs, the complete radiologic response was achieved in 3/5 (60%), partial response in 1/5 (20%) and failure in 1/5 (20%). Among six patients with nonfunctioning PNETs, the complete radiologic response was achieved in 4/6 (66.7%), partial radiologic response in 0/6 (0%) and failure in 2/6 (33.3%). Following a median follow-up of 7 months. One patient with insulinoma showed complete resolution of hypoglycemia-related symptoms. Three postprocedural adverse events occurred, including one case (1/12, 8.3%) of mild acute pancreatitis and two cases (2/12, 16.7%) of abdominal pain. CONCLUSION: EUS-guided RFA for premalignant PCNs and PNETs is feasible and well-tolerated. Efficacy would be further evaluated with continued follow-up of patients.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quiste Pancreático / Neoplasias Pancreáticas / Pancreatitis / Tumores Neuroendocrinos / Tumores Neuroectodérmicos Primitivos / Ablación por Radiofrecuencia Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: Eur J Gastroenterol Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quiste Pancreático / Neoplasias Pancreáticas / Pancreatitis / Tumores Neuroendocrinos / Tumores Neuroectodérmicos Primitivos / Ablación por Radiofrecuencia Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: Eur J Gastroenterol Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido